Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Annalisa LonettiAlessandra CappelliniAlice BertainaFranco LocatelliAndrea PessionFrancesca BuontempoCamilla EvangelistiCecilia EvangelistiEster OrsiniLaura ZamboninLuca Maria NeriAlberto Maria MartelliFrancesca ChiariniPublished in: Journal of hematology & oncology (2016)
These findings indicate that nelarabine in combination with PI3K inhibitors may be a promising therapeutic strategy for the treatment of T-ALL relapsed patients.
Keyphrases
- acute lymphoblastic leukemia
- signaling pathway
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- prognostic factors
- epithelial mesenchymal transition
- multiple myeloma
- diffuse large b cell lymphoma
- patient reported outcomes
- cell proliferation
- endoplasmic reticulum stress